Ajanta Pharma gets USFDA nod for Aripiprazole Tablets

Ajanta Pharma Limited announces the receipt of final approval for Aripiprazole Tablets (2mg, 5mg, 10mg, 15mg, 20mg, 30mg), the bio equivalent generic to Abilify from the USFDA. Ajanta Pharma USA Inc, a wholly owned subsidiary, will be launching the product into the US market soon.

Aripiprazole Tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Applications (ANDAs) of which it has 14 final approvals, including the current approval, 2 tentative approvals and 10 ANDAs under review with the US FDA.

Ajanta Pharma Ltd is currently trading at Rs. 1936, up by Rs. 28.1 or 1.47% from its previous closing of Rs. 1907.9 on the BSE.

The scrip opened at Rs. 1929.95 and has touched a high and low of Rs. 1948.1 and Rs. 1914 respectively. So far 72850 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 16790.47 crore.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2007.25 on 25-Aug-2016 and a 52 week low of Rs. 1103 on 18-Jan-2016. Last one week high and low of the scrip stood at Rs. 2003 and Rs. 1837.7 respectively.

The promoters holding in the company stood at 73.78 % while Institutions and Non-Institutions held 12.06 % and 14.16 % respectively.

The stock is currently trading above its 50 DMA.